Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. KEGG DRUG DrugBank 薬物名（臨床試験情報から抽出） KEGG GENES KEGG PATHWAY 指定難病告示番号
1 Etoposide 💬 1件: Etoposide1件: Etoposide; 2件: TOP2A,
TOP2B 💬		1件: Platinum drug resistance 💬11件: 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 💬
2 Corticotropin 💬 1件: Corticotropin5件: ACTH; Acthar; Adrenocorticotropic hormone; Corticotrophin; Corticotropin; 1件: MC2R 💬5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬12件: 2, 13, 14, 46, 49, 50, 66, 75, 81, 84, 145, 222 💬
3 Cytarabine 💬 1件: Cytarabine1件: Cytarabine; --7件: 11, 13, 14, 25, 49, 60, 65 💬
4 Carmustine 💬 1件: Carmustine1件: Carmustine; --5件: 11, 13, 14, 28, 60 💬
5 Cyclophosphamide 💬 1件: Cyclophosphamide6件: Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan; --44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 💬
6 Dexamethasone 💬 1件: Dexamethasone5件: Decadron; Dexametasona; Dexamethasone; DEXAMETHASONE SODIUM PHOSPHATE; Maxidex; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬22件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 81, 84, 96, 97, 162, 222, 235, 257, 283, 296, 299 💬
7 Melphalan 💬 1件: Melphalan3件: Alkeran; Melphalan; Melphalan Hydrochloride; --15件: 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 💬
8 Methylprednisolone 💬 1件: Methylprednisolone4件: Medrol; Methylprednisolon; Methylprednisolone; Methylprednisolone acetate; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬46件: 2, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 85, 86, 93, 95, 96, 97, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296 💬
9 Prednisolone 💬 1件: Prednisolone3件: Prednisolona; Prednisolone; Prednisolonum; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬42件: 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300 💬
10 Prednisone 💬 1件: Prednisone3件: Prednisona; Prednisone; RAYOS; 1件: NR3C1 💬1件: Neuroactive ligand-receptor interaction 💬45件: 2, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 205, 222, 224, 228, 283, 284, 288, 299, 300, 307, 331 💬
11 Sodium chloride 💬 1件: Sodium chloride6件: Lactated Ringers; Natriumchlorid; REBIF; Saline; SODIUM CHLORIDE; SPORANOX; --20件: 6, 11, 13, 14, 34, 41, 46, 50, 51, 53, 60, 67, 70, 96, 168, 193, 227, 228, 288, 299 💬
12 Rituximab 💬 1件: Rituximab6件: MabThera; Rituxan; RITUXIMAB; Rixathon; Ruxience; Truxima; 1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
13 Eculizumab 💬 1件: Eculizumab2件: ECULIZUMAB; SOLIRIS; 1件: C5 💬11件: Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬7件: 11, 13, 14, 61, 62, 109, 222 💬
14 Dalfampridine 💬 1件: Dalfampridine7件: 4-Aminopyridine; 4-AP; Ampyra; Dalfampridine; FAMPRIDINA; FAMPRIDINE; Fampyra; 4件: KCNA4,
KCNC3,
KCND2,
KCND3 💬		4件: Cortisol synthesis and secretion, Cushing syndrome, Serotonergic synapse, Spinocerebellar ataxia 💬5件: 3, 4, 6, 13, 14 💬
15 Hyaluronidase 💬 1件: Hyaluronidase2件: Hyaluronidase; Hyaluronoglucosaminidase; --5件: 14, 28, 51, 65, 331 💬
16 Hyaluronidase 💬 1件: Hyaluronidase2件: Hyaluronidase; Hyaluronoglucosaminidase; --5件: 14, 28, 51, 65, 331 💬
17 Hyaluronidase 💬 1件: Hyaluronidase2件: HYALURONIDASE; Hyaluronoglucosaminidase; --5件: 14, 28, 51, 65, 331 💬
18 Chlorphenamine 💬 1件: Chlorpheniramine1件: Clorfenamina; 1件: HRH1 💬3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction 💬1件: 14 💬
19 Cyclophosphamide 💬 1件: Cyclophosphamide6件: Ciclofosfamida; Ciclofosfamide; Cyclophosphamid; Cyclophosphamide; Cyclophosphamidum; Cytoxan; --44件: 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 274, 283, 284, 285, 288, 326, 331 💬
20 Fingolimod 💬 1件: Fingolimod3件: Fingolimod; FINGOLIMOD HYDROCHLORIDE; Gilenya; 1件: S1PR1 💬3件: FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬3件: 13, 14, 156 💬
21 Nipocalimab 💬 1件: Nipocalimab1件: Nipocalimab; 1件: FCGRT 💬1件: 💬6件: 11, 14, 46, 49, 53, 61 💬
22 Efgartigimod alfa 💬 1件: Efgartigimod alfa1件: EFGARTIGIMOD ALFA; 1件: FCGRT 💬1件: 💬6件: 11, 14, 35, 53, 63, 162 💬
23 Batoclimab 💬 1件: Batoclimab1件: Batoclimab; 1件: FCGRT 💬1件: 💬2件: 11, 14 💬
24 Rozanolixizumab 💬 1件: Rozanolixizumab1件: ROZANOLIXIZUMAB; 1件: FCGRT 💬1件: 💬3件: 11, 14, 63 💬